Skip to content
Mushroom Retreats
RecruitingEarly phase 1NCT06656702

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population. (The sponsor's summary, shortened.)

Eligibility and contacts on ClinicalTrials.gov

The registry record

Status
Recruiting
Phase
Early phase 1
Conditions
Amyotrophic Lateral Sclerosis
Intervention
Psilocybin
Sponsor
Johns Hopkins University
Ages
18 Years and over
Sex
All
Healthy volunteers
No
Enrolment
24 people (planned)
Start
9 April 2025
Primary completion
30 January 2027
Registry last updated
11 August 2026

Sites (1)

  • Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States (recruiting)

How joining a trial works

Free to take part
Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
Screened first
Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
Eligibility is strict
Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
You may get a placebo
Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
Contact the study team through the registry
Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
Not medical advice
This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications

Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.

Record read from ClinicalTrials.gov API v2, U.S. National Library of Medicine on 28 October 2026. All psilocybin trials